These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37661892)

  • 1. Levels of Synaptic Proteins in Brain and Neurofilament Light Chain in Cerebrospinal Fluid and Plasma of OVT73 Huntington's Disease Sheep Support a Prodromal Disease State.
    Sapp E; Boudi A; Reid SJ; Trombetta BA; Kivisäkk P; Taghian T; Arnold SE; Howland D; Gray-Edwards H; Kegel-Gleason KB; DiFiglia M
    J Huntingtons Dis; 2023; 12(3):201-213. PubMed ID: 37661892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Alterations in Aged OVT73 Sheep Model of Huntington's Disease: An MRI Based Approach.
    Taghian T; Gallagher J; Batcho E; Pullan C; Kuchel T; Denney T; Perumal R; Moore S; Muirhead R; Herde P; Johns D; Christou C; Taylor A; Passler T; Pulaparthi S; Hall E; Chandra S; O'Neill CA; Gray-Edwards H
    J Huntingtons Dis; 2022; 11(4):391-406. PubMed ID: 36189602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging Glucose Metabolism and Dopaminergic Dysfunction in Sheep (
    Williams GK; Akkermans J; Lawson M; Syta P; Staelens S; Adhikari MH; Morton AJ; Nitzsche B; Boltze J; Christou C; Bertoglio D; Ahamed M
    ACS Chem Neurosci; 2024 Nov; 15(21):4082-4091. PubMed ID: 39420554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
    Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
    Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal synaptosomes from Hdh140Q/140Q knock-in mice have altered protein levels, novel sites of methionine oxidation, and excess glutamate release after stimulation.
    Valencia A; Sapp E; Kimm JS; McClory H; Ansong KA; Yohrling G; Kwak S; Kegel KB; Green KM; Shaffer SA; Aronin N; DiFiglia M
    J Huntingtons Dis; 2013; 2(4):459-75. PubMed ID: 24696705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further molecular characterisation of the OVT73 transgenic sheep model of Huntington's disease identifies cortical aggregates.
    ; Reid SJ; Patassini S; Handley RR; Rudiger SR; McLaughlan CJ; Osmand A; Jacobsen JC; Morton AJ; Weiss A; Waldvogel HJ; MacDonald ME; Gusella JF; Bawden CS; Faull RL; Snell RG
    J Huntingtons Dis; 2013; 2(3):279-95. PubMed ID: 25062676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease.
    Bondulich MK; Phillips J; Cañibano-Pico M; Nita IM; Byrne LM; Wild EJ; Bates GP
    Brain Commun; 2024; 6(1):fcae030. PubMed ID: 38370446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
    Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
    J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.
    Rodrigues FB; Byrne LM; Tortelli R; Johnson EB; Wijeratne PA; Arridge M; De Vita E; Ghazaleh N; Houghton R; Furby H; Alexander DC; Tabrizi SJ; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington's disease: a semi-mechanistic model-based analysis.
    Machacek M; Garcia-Montoya E; McColgan P; Sanwald-Ducray P; Mazer NA
    Front Neurosci; 2024; 18():1420198. PubMed ID: 39022122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients.
    Szejko N; Picón C; García-Caldentey J; de Yebenes JG; Alvarez-Cermeño JC; Villar LM; López-Sendón Moreno JL
    PLoS Curr; 2018 Aug; 10():. PubMed ID: 30258698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
    Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
    Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multi-Omic Huntington's Disease Transgenic Sheep-Model Database for Investigating Disease Pathogenesis.
    Mears ER; Handley RR; Grant MJ; Reid SJ; Day BT; Rudiger SR; McLaughlan CJ; Verma PJ; Bawden SC; Patassini S; Unwin RD; Cooper GJS; Gusella JF; MacDonald ME; Brauning R; Maclean P; Pearson JF; Waldvogel HJ; Faull RLM; Snell RG
    J Huntingtons Dis; 2021; 10(4):423-434. PubMed ID: 34420978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.
    Soylu-Kucharz R; Sandelius Å; Sjögren M; Blennow K; Wild EJ; Zetterberg H; Björkqvist M
    Sci Rep; 2017 Oct; 7(1):14114. PubMed ID: 29074982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease.
    Al Shweiki MR; Oeckl P; Pachollek A; Steinacker P; Barschke P; Halbgebauer S; Anderl-Straub S; Lewerenz J; Ludolph AC; Bernhard Landwehrmeyer G; Otto M
    Mov Disord; 2021 Feb; 36(2):492-497. PubMed ID: 33006791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington's disease: Korean cohort data.
    Hwang YS; Oh E; Kim M; Lee CY; Kim HS; Chung SJ; Sung YH; Yoon WT; Cho JH; Lee JH; Kim HJ; Chang HJ; Jeon B; Woo KA; Ko SB; Kwon KY; Moon J; Shin C; Kim YE; Lee JY
    J Neurol Sci; 2023 Sep; 452():120744. PubMed ID: 37541133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.